Galapagos NV (LON:0JXZ)

London flag London · Delayed Price · Currency is GBP · Price in EUR
25.34
+0.74 (3.02%)
At close: Jul 9, 2025
5.32%
Market Cap 1.48B
Revenue (ttm) 241.09M
Net Income (ttm) -141.83M
Shares Out n/a
EPS (ttm) -2.15
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,365
Average Volume 15,324
Open 24.73
Previous Close 24.60
Day's Range 24.64 - 25.36
52-Week Range 19.99 - 30.88
Beta -0.01
RSI 68.05
Earnings Date Jul 23, 2025

About Galapagos NV

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company’s pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T ... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1999
Employees 704
Stock Exchange London Stock Exchange
Ticker Symbol 0JXZ
Full Company Profile

Financial Performance

In 2024, Galapagos NV's revenue was 275.65 million, an increase of 14.99% compared to the previous year's 239.72 million. Earnings were 74.08 million, a decrease of -65.01%.

Financial numbers in EUR Financial Statements

News

There is no news available yet.